Grufity logo
Grufity logo
CPIX

CPIX - Cumberland Pharmaceuticals Inc Stock Price, Fair Value and News

$6.71-0.02 (-0.30%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

19/100

CPIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

19/100

CPIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CPIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPIX Price Action

Last 7 days

1.5%

Last 30 days

-5.9%

Last 90 days

53.9%

Trailing 12 Months

94.5%

CPIX RSI Chart

CPIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPIX Valuation

Market Cap

100.5M

Price/Earnings (Trailing)

-13.62

Price/Sales (Trailing)

2.4

EV/EBITDA

-37.39

Price/Free Cashflow

73.34

CPIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CPIX Fundamentals

CPIX Revenue

Revenue (TTM)

41.9M

Rev. Growth (Yr)

-22.04%

Rev. Growth (Qtr)

-33.24%

CPIX Earnings

Earnings (TTM)

-7.4M

Earnings Growth (Yr)

-361.69%

Earnings Growth (Qtr)

-133.03%

CPIX Profitability

EBT Margin

-17.17%

Return on Equity

-34.12%

Return on Assets

-10.4%

Free Cashflow Yield

1.36%

CPIX Investor Care

Shares Dilution (1Y)

0.27%

Diluted EPS (TTM)

-0.49

Revenue & Growth

How Cumberland Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202641.9M---
202541.1M42.1M41.3M44.5M
202438.8M37.8M36.8M37.9M
202340.1M40.7M39.3M39.6M
202236.6M37.9M41.2M42.0M
202139.6M39.1M37.9M36.0M
202034.0M34.2M36.5M37.4M
201932.2M34.5M35.6M34.4M
201837.4M35.8M30.5M29.3M
201734.9M36.2M38.6M41.2M
201632.6M31.1M32.0M33.0M
201537.5M36.7M34.8M33.5M
201429.9M32.5M35.7M36.9M
201348.9M43.6M37.6M32.0M
201250.7M48.7M48.2M48.9M
2011-50.1M50.9M51.1M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cumberland Pharmaceuticals Inc

CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
 CEO
 WEBSITEcumberlandpharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES85

Cumberland Pharmaceuticals Inc Frequently Asked Questions

CPIX is the stock ticker symbol of Cumberland Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Cumberland Pharmaceuticals Inc is 100.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, CPIX's PE ratio (Price to Earnings) is -13.62 and Price to Sales (PS) ratio is 2.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPIX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cumberland Pharmaceuticals Inc has provided 0.039 (multiply by 100 for percentage) rate of return.